Global in-vitro diagnostics (IVD) market was valued at $108.3 billion in 2025 and is growing at a CAGR of 5.7% during the forecast period (2026-2035). The marker growth is driven by the rising prevalence of chronic diseases (cancer, diabetes), demand for rapid Point-of-Care (POC) testing, technological advancements like Molecular Diagnostics & NGS, a growing elderly population, and increased self-testing. Key factors fueling this expansion include supportive government initiatives and a shift towards personalized medicine, while challenges involve stringent regulations and high costs. The market is dominated by reagents & kits, with North America leading; however, Asia-Pacific showing the fastest growth, focusing on improving sensitivity, specificity, and speed in diagnostics.
Browse the full report description of “In-Vitro Diagnostics (IVD) Market Size, Share & Trends Analysis By Application (Diabetes, Infectious Diseases, Cancer, Drug Testing, Autoimmune Diseases and Others), By Product (Instruments, Reagents and Software and Services), By Technology (Immunodiagnostics, Molecular Diagnostics, Hematology, Tissue Diagnostics and Others), By End-User (Hospitals and Clinics, Diagnostic Laboratories and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/in-vitro-diagnostics-market-size
Regulatory approvals such as CE, UKCA, and FDA facilitate the broader clinical adoption of innovative diagnostic technologies, thereby driving market growth. For instance, in January 2026, Oxford Nanopore obtained CE and UKCA certification for its first diagnostic device, the GridION Dx, marking it as the company's initial in vitro diagnostic (IVD) product in the UK and Europe. This approval signifies compliance with stringent international quality, safety, and performance standards, enhancing prospects for use in clinical markets. The GridION Dx focused on infectious disease characterization, initially collaborating with bioMérieux to integrate with the AmPORE-TB assay for multidrug-resistant tuberculosis. Currently in clinical trials, this partnership aims to develop sequencing-based tuberculosis testing for clinical use.
The rising prevalence of chronic diseases is leading to an increased demand for routine diagnostic testing, disease screening, and biomarker monitoring, which is driving market growth.
Major Participants Influencing the Evolution of the In-Vitro Diagnostics (IVD) Market
The in-vitro diagnostics (IVD) market comprises several established participants, including Abbott Laboratories, Danaher Corp., Hoffmann-La Roche Ltd., Siemens Healthineers AG, and Thermo Fisher Scientific Inc., among others. These organizations contribute to market development through investments in diagnostic technologies and the integration of digital healthcare capabilities such as telemedicine platforms, electronic health records, remote patient monitoring systems, and AI-enabled clinical tools, which collectively support advancements in healthcare delivery globally.
Market Coverage
Key questions addressed by the report.
Global In-Vitro Diagnostics (IVD) Market Report Segment
By Application
By Product
By Technology
By End User
Global In-Vitro Diagnostics (IVD) Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/in-vitro-diagnostics-market-size